LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Home・Lista de Ações・MannKind Corp
Search

MannKind Corp

Fechado

SetorSaúde

3.21 -2.43

Compra Forte

Atualização de preço 13 de mai. de 2026, 19:59 UTC

ComprarVender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

3.11

Máximo

3.2800000000000002

Indicadores-chave

By Trading Economics

Rendimento

-671K

-17M

Vendas

-22M

90M

P/E

Médio do Setor

140.5

51.415

EPS

-0.02

Margem de lucro

-18.431

Funcionários

591

EBITDA

5.9M

3.4M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+129.88% upside

Dividendos

By Dow Jones

Próximos Ganhos

5 de ago. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

170M

1B

Abertura anterior

5.64

Fecho anterior

3.21

Sentimento de Notícias

By Acuity

31%

69%

88 / 346 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

4.079 / 4.323 Suporte e Resistência

MannKind Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

13 de mai. de 2026, 22:54 UTC

Ganhos

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

DJ

Ler

13 de mai. de 2026, 23:51 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

DJ

Ler

13 de mai. de 2026, 23:51 UTC

Conversa de Mercado

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

DJ

Ler

13 de mai. de 2026, 23:45 UTC

Conversa de Mercado

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

DJ

Ler

13 de mai. de 2026, 23:45 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

DJ

Ler

13 de mai. de 2026, 23:17 UTC

Ganhos

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

DJ

Ler

13 de mai. de 2026, 23:16 UTC

Ganhos

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

DJ

Ler

13 de mai. de 2026, 23:15 UTC

Ganhos

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

DJ

Ler

13 de mai. de 2026, 23:14 UTC

Ganhos

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

DJ

Ler

13 de mai. de 2026, 23:02 UTC

Conversa de Mercado
Ganhos

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

DJ

Ler

13 de mai. de 2026, 22:59 UTC

Conversa de Mercado
Ganhos

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

DJ

Ler

13 de mai. de 2026, 22:24 UTC

Ganhos

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

DJ

Ler

13 de mai. de 2026, 22:23 UTC

Ganhos

Xero FY International Organic Revenue Growth 25%>XRO.AU

DJ

Ler

13 de mai. de 2026, 22:23 UTC

Ganhos

Xero FY International Revenue Growth 47%>XRO.AU

DJ

Ler

13 de mai. de 2026, 22:22 UTC

Ganhos

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

DJ

Ler

13 de mai. de 2026, 22:19 UTC

Ganhos

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

DJ

Ler

13 de mai. de 2026, 22:19 UTC

Ganhos

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

DJ

Ler

13 de mai. de 2026, 22:18 UTC

Ganhos

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

DJ

Ler

13 de mai. de 2026, 22:16 UTC

Ganhos

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

DJ

Ler

13 de mai. de 2026, 22:15 UTC

Ganhos

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

DJ

Ler

13 de mai. de 2026, 22:15 UTC

Ganhos

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

DJ

Ler

13 de mai. de 2026, 22:13 UTC

Ganhos

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

DJ

Ler

13 de mai. de 2026, 22:12 UTC

Ganhos

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

DJ

Ler

13 de mai. de 2026, 22:11 UTC

Ganhos

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

DJ

Ler

13 de mai. de 2026, 22:11 UTC

Ganhos

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

DJ

Ler

13 de mai. de 2026, 22:10 UTC

Ganhos

Xero Did Not Declare a Dividend>XRO.AU

DJ

Ler

13 de mai. de 2026, 22:10 UTC

Ganhos

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

DJ

Ler

13 de mai. de 2026, 22:09 UTC

Ganhos

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

DJ

Ler

13 de mai. de 2026, 22:00 UTC

Ganhos

Cisco to Shed Jobs for All-In AI Push -- Update

DJ

Ler

13 de mai. de 2026, 21:11 UTC

Ganhos

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

DJ

Ler

Comparação entre Pares

Variação de preço

MannKind Corp Previsão

Preço-alvo

By TipRanks

129.88% parte superior

Previsão para 12 meses

Média 7.54 USD  129.88%

Máximo 10 USD

Mínimo 4.75 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para MannKind Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

7

Comprar

1

Manter

0

Vender

Com base em 8 analistas que deram avaliações de ações para MannKind Corp - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

4.079 / 4.323Suporte e Resistência

Curto Prazo

Bullish Evidence

Bullish events outweigh bearish events.

Médio Prazo

Bearish Evidence

All events are bearish.

Longo Prazo

Weak Bearish Evidence

Bearish events outweigh bullish events.

Sentimento

By Acuity

88 / 346 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Outras ações do setor

LLY

Eli Lilly and Co.

1,015.5

↑ +2.79%

JNJ

Johnson and Johnson

230.41

↑ +2.69%

ABBV

AbbVie Inc

208.54

↑ +0.36%

UNH

UnitedHealth Group Inc

400.53

↑ +1.04%

AZN

AstraZeneca PLC

187.75

↑ +1.77%
help-icon Live chat